Abstract:BackgroundHER2 is an oncogene, expression of which leads to poor prognosis in 30% of breast cancer patients. Although trastuzumab is apparently an effective therapy against HER2-positive tumors, its systemic toxicity and resistance in the majority of patients restricts its applicability. In this study we evaluated the effects of phenethyl isothiocyanate (PEITC) in HER2-positive breast cancer cells.MethodsMDA-MB-231 and MCF-7 breast cancer cells stably transfected with HER2 (high HER2 (HH)) were used in this study. The effect of PEITC was evaluated using cytotoxicity and apoptosis assay in these syngeneic cells. Western blotting was used to delineate HER2 signaling. SCID/NOD mice were implanted with MDA-MB-231 (HH) xenografts.ResultsOur results show that treatment of MDA-MB-231 and MCF-7 cells with varying concentrations of PEITC for 24 h extensively reduced the survival of the cells with a 50% inhibitory concentration (IC50) of 8 μM in MDA-MB-231 and 14 μM in MCF-7 cells. PEITC treatment substantially decreased the expression of HER2, epidermal growth factor receptor (EGFR) and phosphorylation of signal transducer and activator of transcription 3 (STAT3) at Tyr-705. The expression of BCL-2-associated × (BAX) and BIM proteins were increased, whereas the levels of B cell lymphoma-extra large (BCL-XL) and X-linked inhibitor of apoptosis protein (XIAP) were significantly decreased in both the cell lines in response to PEITC treatment. Substantial cleavage of caspase 3 and poly-ADP ribose polymerase (PARP) were associated with PEITC-mediated apoptosis in MDA-MB-231 and MCF-7 cells. Notably, transient silencing of HER2 decreased and overexpressing HER2 increased the effects of PEITC. Furthermore, reactive oxygen species (ROS) generation, mitochondrial depolarization and apoptosis by PEITC treatment were much higher in breast cancer cells expressing higher levels of HER2 (HH) as compared to parent cell lines. The IC50 of PEITC following 24 h of treatment was reduced remarkably to 5 μM in MDA-MB-231 (HH) and 4 μM in MCF-7 (HH) cells, stably overexpressing HER2. Oral administration of 12 μM PEITC significantly suppressed the growth of breast tumor xenografts in SCID/NOD mice. In agreement with our in vitro results, tumors from PEITC-treated mice demonstrated reduced HER2, EGFR and STAT3 expression and increased apoptosis as revealed by cleavage of caspase 3 and PARP. In addition our results show that PEITC can enhance the efficacy of doxorubicin.ConclusionsOur results show a unique specificity of PEITC in inducing apoptosis in HER2-expressing tumor cells in vitro and in vivo and enhancing the effects of doxorubicin. This unique specificity of PEITC offers promise to a subset of breast cancer patients overexpressing HER2.

Cytotoxic Comparison Between Two Recombinant Immunotoxins of HELβ1-PE38KDEL and HELβ1-PE33 in Selective Therapy for Breast Cancer

Synergistic Cytotoxic Effect of Immunotoxin HEL PE38KDEL and Cis Platin Against Tumor Cells

Synergistic effect between the recombined immunotoxin HELβ1-PE38KDEL and cisplatin in the cytotoxic effect against breast cancer cells

Preparation and Characterization of PE38KDEL-loaded Anti-Her2 Nanoparticles for Targeted Cancer Therapy

In Vitro and in Vivo Antitumor Effects of the Recombinant Immunotoxin IL6(T23)-PE38KDEL in Multiple Myeloma.

PE38KDEL-loaded Anti-Her2 Nanoparticles Inhibit Breast Tumor Progression with Reduced Toxicity and Immunogenicity

HER2-targeted immunotoxins with low nonspecific toxicity and immunogenicity

In vitro and in vivo studies of antitumor effects of the recombinant immunotoxin MSH-PE38KDEL on melanoma.

Preparation of Diphtheria and Pseudomonas Exotoxin A Immunotoxins and Evaluation of Their Cytotoxicity Effect on SK-BR-3, BT-474, and MDA-MB-231 Breast Cancer Cell Lines

Manufacture and Evaluation of a HER2-positive Breast Cancer Immunotoxin 4D5fv-Pe25

Expression and functional detection of recombinant immunotoxins anti-B7-H4-scFv/PE38KDEL

[The Comparison Between the Killing Effects of Two Anti-T Immunotoxins on Target Cells]

Reduction of non-specific toxicity of immunotoxin by intein mediated reconstitution on target cells

Expression, purification, and characterization of an immunotoxin containing a humanized anti-CD25 single-chain fragment variable antibody fused to a modified truncated Pseudomonas exotoxin A.

Data from Treatment of Hepatocellular Carcinoma in Mice with PE38KDEL Type I Mutant-Loaded Poly(lactic-Co-glycolic Acid) Nanoparticles Conjugated with Humanized SM5-1 F(ab′) Fragments

In silico and in vitro evaluation of a PE38 and Nb‐based recombinant immunotoxin targeting the GRP78 receptor in cancer cells

Selective Cytotoxicity to HER2-Positive Tumor Cells by a Recombinant E23sfv-Td-tbid Protein Containing a Furin Cleavage Sequence

Expression of Recombinant Target Toxin IL-6(23)-PE40KDEL in Pichia Pastoris and Activity of Expressed Product

Design Optimization and Characterization of Her2/neu-targeted Immunotoxins: Comparative in Vitro and in Vivo Efficacy Studies

Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models

A Bispecific Immunotoxin (IHPP) with a Long Half-Life Targeting HER2 and PDGFRβ Exhibited Improved Efficacy Against HER2-positive Tumors in a Mouse Xenograft Model.